Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04893707

The Study of CM310 in Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis Clinical Trial

Official title:
An Open, Multicenter,Open-label Extension Study to Evaluate the Safety and Efficacy of CM310 in Patients With Atopic Dermatitis

Clinical Trial Summary

This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in patients with atopic dermatitis (AD).

Clinical Trial Description

The secondary objective of the study is to assess the immunogenicity of CM310 in patients with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04893707
Study type Interventional
Source Keymed Biosciences Co.Ltd
Contact
Status Recruiting
Phase Phase 2
Start date June 7, 2021
Completion date June 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03054428 - Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Phase 3
Active, not recruiting NCT05899816 - A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) Phase 3
Completed NCT03985943 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Completed NCT03989349 - Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Recruiting NCT04921345 - Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04893941 - Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT04444752 - A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05203380 - Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Withdrawn NCT05056779 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Phase 3
Active, not recruiting NCT05590585 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Phase 4
Completed NCT04805411 - Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 2
Recruiting NCT05186922 - The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis Phase 1/Phase 2
Recruiting NCT03057860 - TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
Active, not recruiting NCT03989206 - Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT05671432 - The Study of CM326 in Moderate-to-severe Atopic Dermatitis Phase 2
Not yet recruiting NCT06158490 - A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT05984784 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT05017480 - A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Phase 2